Relieve your patient’s pain and help them lead an active future.
You want your patients to be comfortable and mobile. Treating canine OA from the earliest diagnosed stage is key, but the fear of long-term risks can often get in the way of prescribing medication.
Galliprant is a first-in-class non-COX-inhibiting NSAID1 that works differently.
†If Galliprant is used long-term, appropriate monitoring is recommended.
Proper weight management helps reduce stress on joints while promoting greater energy and activity. Maintaining a healthy weight helps keep joints limber and muscles strong.
Regular physical activity helps with appropriate weight control. Additionally, low impact exercise helps benefit dogs with advanced OA.
Physical rehabilitation techniques relieve pain, help joint mobility and muscle strength, and promote cartilage, tendon and ligament health.
Chondroprotectants promote healthy joint lubrication and help repair damaged cartilage.
Additional therapies may support the primary tools for managing chronic pain and disability associated with OA.
Recognizing how to prevent and treat OA is important, but it doesn’t stop there. Find more useful resources below to get up to speed on canine OA.
COAST is an innovative canine OA staging tool designed by a consortium of international experts in veterinary surgery and pain management. With COAST, you can start the conversation about canine OA with pet owners before it sets in, and monitor OA over time.
Feel inspired by the stories of veterinarians making a meaningful impact in the lives of their patients and the families that trust them to deliver the best care for their beloved family member.
Find out how Galliprant® (grapiprant tablets) allows you to provide daily relief for canine OA pain.
Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.
Contact your Elanco or distributor representative, or call Elanco (1-888-545-5973) to discover how you can incorporate Galliprant into your canine OA protocol today.
© 2022 Elanco or its affiliates. Galliprant, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.